Literature DB >> 9090333

Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.

H Y Meltzer1, J Rabinowitz, M A Lee, P A Cola, R Ranjan, R L Findling, P A Thompson.   

Abstract

OBJECTIVE: The age at onset of schizophrenia for males has usually but not always been reported to be less than that for females. Early onset has also been associated with poor response to neuroleptic treatment and worse long-term outcome. The authors compared age at onset in neuroleptic-resistant and -responsive schizophrenic patients to determine whether the gender difference in age at onset is related to response to neuroleptic treatment.
METHOD: The subjects were 322 patients with schizophrenia or schizoaffective disorder who were consecutively admitted to a university hospital-based research program.
RESULTS: Analysis of variance showed significant relationship between age at onset and both gender and longterm responsivity to neuroleptic drugs. The mean ages at onset in the neuroleptic-responsive men (mean = 21.2 years, SD = 6.1, N = 75), neuroleptic-resistant men (mean = 19.4 years, SD = 4.7, N = 119), and neuroleptic-resistant women (mean = 20.1 years, SD = 6.3, N = 77) were fairly similar, whereas that of the neuroleptic-responsive women (mean = 24.2 years, SD = 8.7, N = 51) was significantly greater than for all other groups. A simple effects model indicated that male and female neuroleptic-resistant patients did not differ significantly in mean age at onset, whereas male and female neuroleptic-responsive patients did. The effect of gender and neuroleptic responsivity on age at onset was related to schizophrenic subtype.
CONCLUSIONS: These results confirm previous data indicating neuroleptic resistance is associated with early onset. The finding that the difference in age at onset between males and females is smaller in neuroleptic-resistant patients than in neuroleptic-responsive patients suggests that neuroleptic-resistant patients differ premorbidly as well as after onset of illness.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090333     DOI: 10.1176/ajp.154.4.475

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  31 in total

1.  Trajectories and antecedents of treatment response over time in early-episode psychosis.

Authors:  Stephen Z Levine; J Rabinowitz
Journal:  Schizophr Bull       Date:  2008-10-09       Impact factor: 9.306

2.  Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria.

Authors:  Mark S Ezeme; Richard Uwakwe; Appolos C Ndukuba; Monday N Igwe; Paul C Odinka; Kennedy Amadi; Nichodemus O Obayi
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

Review 3.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Processing speed and neurodevelopment in adolescent-onset psychosis: cognitive slowing predicts social function.

Authors:  Peter Bachman; Tara A Niendam; Maria Jalbrzikowski; Maria Jalbrzikowkski; Chan Y Park; Melita Daley; Tyrone D Cannon; Carrie E Bearden
Journal:  J Abnorm Child Psychol       Date:  2012-05

5.  How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials.

Authors:  Myrto T Samara; Adriani Nikolakopoulou; Georgia Salanti; Stefan Leucht
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

6.  Genetic variability testing of neurodevelopmental genes in schizophrenic patients.

Authors:  Tea Terzić; Matej Kastelic; Vita Dolžan; Blanka Kores Plesničar
Journal:  J Mol Neurosci       Date:  2014-12-23       Impact factor: 3.444

Review 7.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

8.  Accessing Gene Expression in Treatment-Resistant Schizophrenia.

Authors:  Patricia N Moretti; Vanessa K Ota; Eduardo S Gouvea; Mariana Pedrini; Marcos L Santoro; Fernanda Talarico; Leticia M Spindola; Carolina Muniz Carvalho; Cristiano Noto; Gabriela Xavier; Elisa Brietzke; Ary Gadelha; Rodrigo Bressan; Jair Mari; Sintia Belangero
Journal:  Mol Neurobiol       Date:  2018-01-26       Impact factor: 5.590

9.  Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia.

Authors:  Kari Hänninen; Heikki Katila; Marika Saarela; Riikka Rontu; Kari M Mattila; Meng Fan; Mikko Hurme; Terho Lehtimäki
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-09-27       Impact factor: 5.270

10.  Prescription stimulant use is associated with earlier onset of psychosis.

Authors:  Lauren V Moran; Grace A Masters; Samira Pingali; Bruce M Cohen; Elizabeth Liebson; R P Rajarethinam; Dost Ongur
Journal:  J Psychiatr Res       Date:  2015-09-21       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.